Xilio Therapeutics Reports Q4 Net Income, Extends Cash Runway to 2027, and Advances Pipeline

summarizeSummary

Xilio Therapeutics announced a significant financial turnaround with a Q4 2025 net income of $10.4 million, a substantial increase in cash, and an extended cash runway through the end of 2027, alongside positive pipeline advancements.

check_boxKey Events

• Q4 2025 Net Income Reported

  The company reported a net income of $10.4 million for Q4 2025, a significant improvement from a $13.1 million net loss in Q4 2024.

• Cash Runway Extended to 2027

  Xilio Therapeutics anticipates its existing cash and cash equivalents will fund operations through the end of 2027, providing substantial financial stability.

• Strong Cash Position

  The company ended 2025 with $137.5 million in cash and cash equivalents, up from $55.3 million at the end of 2024, bolstered by warrant exercises and a follow-on offering.

• Pipeline Advancement Updates

  Provided updates on multiple immuno-oncology programs, including planned IND submissions for XTX501 in mid-2026 and masked T cell engager programs in 2027.

auto_awesomeAnalysis

Xilio Therapeutics delivered a strong financial and operational update, highlighted by a surprising swing to net income in Q4 2025 and a significantly improved cash position. The company's cash and cash equivalents of $137.5 million as of December 31, 2025, combined with recent capital raises, are projected to fund operations through the end of 2027, substantially de-risking the company's near-term financial outlook. This extended runway provides critical stability for a clinical-stage biotechnology company. Furthermore, the company provided positive updates on its pipeline, including planned IND submissions for XTX501 and masked T cell engager programs, indicating active progress towards clinical milestones.